Elevated baseline interleukin-6 levels independently predicted long-term cardiovascular mortality in NYHA class III heart failure patients (12.8 pg/ml in non-survivors vs 5.6 pg/ml in survivors, P<0.003).
Cohort (n=91)
Do plasma cytokine levels improve risk stratification for cardiovascular death in NYHA class III patients with LVEF <40%?
Interleukin-6 levels are predictive of long-term survival in NYHA class III heart failure patients, but may have limited value for short-term risk stratification for cardiac transplantation.
p-value: p=<0.003
AIMS: Elevated plasma levels of proinflammatory cytokines have been reported in patients with congestive heart failure. The purpose of this study was to assess whether cytokines improve risk stratification in a homogeneous group of NYHA class III patients with a left ventricular ejection fraction or =1 year), multivariate Cox regression analysis revealed an independent prognostic power for interleukin-6, which was further improved by combining with left ventricular ejection fraction and peak VO2, while for short-term survival (up to 6 months) interleukin-6 did not allow risk stratification. CONCLUSION: In NYHA class III patients, plasma concentrations of interleukin-6 are predictive of long-term survival. However, its value may be limited for clinical decision-making for cardiac transplantation (short-term survival).
Robert Kell (Tue,) conducted a cohort in Congestive heart failure (n=91). Plasma cytokines (interleukin-6) was evaluated on Cardiovascular death (p=<0.003). Elevated baseline interleukin-6 levels independently predicted long-term cardiovascular mortality in NYHA class III heart failure patients (12.8 pg/ml in non-survivors vs 5.6 pg/ml in survivors, P<0.003).